Karen E Willard-Gallo

List of Publications by Year
in descending order

80 papers	5,337 citations	136885 32 h-index	91828 69 g-index
82 all docs	82 docs citations	82 times ranked	8984 citing authors

#	Article	IF	Citations
1	Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. Cancers, 2022, 14, 682.	1.7	6
2	Characterization of Immunoactive and Immunotolerant CD4+ T Cells in Breast Cancer by Measuring Activity of Signaling Pathways That Determine Immune Cell Function. Cancers, 2022, 14, 490.	1.7	7
3	A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma. Diagnostics, 2022, 12, 539.	1.3	2
4	T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy. Nature Communications, 2022, 13, 2259.	5.8	32
5	Demographic and laboratory determinants of humoral immune responses and impact of different anti-SARS-CoV-2 vaccine platforms in patients with cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2022, 40, 1543-1543.	0.8	0
6	Impact of cancer diagnosis, stage, and systemic therapies on immunogenicity after COVID-19 vaccination in patients with cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2022, 40, 1537-1537.	0.8	0
7	Targeting <scp>CTLA</scp>â€4 in cancer: Is it the ideal companion for <scp>PD</scp>â€1 blockade immunotherapy combinations?. International Journal of Cancer, 2021, 149, 31-41.	2.3	23
8	Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. Molecular Diagnosis and Therapy, 2021, 25, 409-424.	1.6	33
9	Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors. Nature Cancer, 2021, 2, 611-628.	5.7	30
10	Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment. Frontiers in Molecular Biosciences, 2021, 8, 673042.	1.6	19
11	A review of immune checkpoint blockade in breast cancer. Seminars in Oncology, 2021, 48, 208-225.	0.8	11
12	Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. Breast, 2021, 59, 183-192.	0.9	10
13	Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. Journal of Clinical Investigation, 2021, 131, .	3.9	70
14	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2021, 7, 150.	2.3	112
15	The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History. Pathology and Oncology Research, 2020, 26, 1221-1228.	0.9	5
16	Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. Cancer Treatment Reviews, 2020, 84, 101947.	3.4	35
17	Radiomics and â€œradi-â€¦omicsâ€•in cancer immunotherapy: a guide for clinicians. Critical Reviews in Oncology/Hematology, 2020, 154, 103068.	2.0	26
18	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. Nature Communications, 2020, 11, 6335.	5.8	46

#	Article	IF	Citations
19	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	2.3	106
20	Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?. Translational Oncology, 2020, 13, 100811.	1.7	46
21	Immune Checkpoint Inhibitor-Induced Pancreatic Injury: Imaging Findings and Literature Review. Targeted Oncology, 2020, 15, 25-35.	1.7	25
22	The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy. ESMO Open, 2020, 5, e000544.	2.0	95
23	RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies. Frontiers in Genetics, 2020, 11, 598118.	1.1	18
24	Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. Journal of the National Cancer Institute, 2019, 111, 69-77.	3.0	60
25	LAG3: The Biological Processes That Motivate Targeting This Immune Checkpoint Molecule in Human Cancer. Cancers, 2019, 11, 1213.	1.7	75
26	Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. Critical Reviews in Oncology/Hematology, 2019, 142, 35-43.	2.0	18
27	Tumor-Derived Thymic Stromal Lymphopoietin Expands Bone Marrow B-cell Precursors in Circulation to Support Metastasis. Cancer Research, 2019, 79, 5826-5838.	0.4	21
28	Age-related changes in the BACH2 and PRDM1 genes in lymphocytes from healthy donors and chronic lymphocytic leukemia patients. BMC Cancer, 2019, 19, 81.	1.1	9
29	Immune evasion before tumour invasion in early lung squamous carcinogenesis. Nature, 2019, 571, 570-575.	13.7	227
30	Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. Cancers, 2019, 11, 305.	1.7	51
31	BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. Cancer Letters, 2019, 450, 88-97.	3.2	33
32	Significance of TIM3 expression in cancer: From biology to the clinic. Seminars in Oncology, 2019, 46, 372-379.	0.8	49
33	FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer. EBioMedicine, 2019, 39, 226-238.	2.7	36
34	Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. JCI Insight, 2019, 4, .	2.3	182
35	The Abscopal Effect in the Era of Cancer Immunotherapy: a Spontaneous Synergism Boosting Anti-tumor Immunity?. Targeted Oncology, 2018, 13, 113-123.	1.7	26
36	Immune Infiltration in Invasive Lobular Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 768-776.	3.0	76

#	Article	IF	Citations
37	Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?. Critical Reviews in Oncology/Hematology, 2018, 126, 135-144.	2.0	14
38	The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer. Seminars in Cancer Biology, 2018, 52, 66-74.	4.3	18
39	Inflammatory Stroma of Lymphoepithelioma-like Carcinoma of the Cervix. International Journal of Gynecological Pathology, 2018, 37, 482-487.	0.9	7
40	Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer. Frontiers in Immunology, 2018, 9, 2660.	2.2	65
41	Cancer immunotherapy-associated hypophysitis. Seminars in Oncology, 2018, 45, 181-186.	0.8	47
42	Aging and Malignant Hemopathies: A Complex Multistep Process. , 2018, , 1-13.		1
43	Quantifying Tertiary Lymphoid Structure-Associated Genes in Formalin-Fixed Paraffin-Embedded Breast Cancer Tissues. Methods in Molecular Biology, 2018, 1845, 139-157.	0.4	6
44	Immunity drives TET1 regulation in cancer through NF-ÎºB. Science Advances, 2018, 4, eaap7309.	4.7	64
45	Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. Cancer Treatment Reviews, 2017, 57, 8-15.	3.4	75
46	Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Modern Pathology, 2017, 30, 1204-1212.	2.9	81
47	P3.02c-087 The Relationship of TILs and PD-L1 Expression in NSCLC Adenocarcinoma in Little to Non-Smokers with Driver Mutations and Outcome Parameters. Journal of Thoracic Oncology, 2017, 12, S1331.	0.5	2
48	Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. OncoImmunology, 2017, 6, e1257452.	2.1	169
49	PD-1 hi CXCR5 â^' CD4 + T FH Cells Play Defense in Cancer and Offense in Arthritis. Trends in Immunology, 2017, 38, 875-878.	2.9	26
50	Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Critical Reviews in Oncology/Hematology, 2017, 120, 13-21.	2.0	56
51	Immunology of Solid Tumors Beyond Tumor-Infiltrating Lymphocytes: The Role of Tertiary Lymphoid Structures. , 2017, , 259-280.		0
52	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Nonâ€“Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24, 311-335.	2.4	530
53	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	2.4	469
54	FOXP1 is a regulator of quiescence in healthy human CD4⁺ T cells and is constitutively repressed in T cells from patients with lymphoproliferative disorders. European Journal of Immunology, 2017, 47, 168-179.	1.6	35

#	Article	IF	Citations
55	CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight, 2017, 2, .	2.3	258
56	Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. Frontiers in Immunology, 2017, 8, 1412.	2.2	80
57	Circulating (CD3^{â^'}CD19⁺CD20^{â^'}IgD^{â^'}CD27^{high}CD38^{high}) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?. Mediators of Inflammation, 2016, 2016, 1-10.	1.4	18
58	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164.	2.9	230
59	Transcription Factors and Checkpoint Inhibitor Expression with Age: Markers of Immunosenescence?. Blood, 2016, 128, 5983-5983.	0.6	0
60	IRF5: a rheostat for tumorâ€infiltrating lymphocyte trafficking in breast cancer?. Immunology and Cell Biology, 2015, 93, 425-426.	1.0	9
61	Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?. Current Breast Cancer Reports, 2015, 7, 59-70.	0.5	1
62	Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome. Cell Reports, 2015, 13, 277-289.	2.9	179
63	A Simple and Rapid Protocol to Non-enzymatically Dissociate Fresh Human Tissues for the Analysis of Infiltrating Lymphocytes. Journal of Visualized Experiments, 2014, , .	0.2	33
64	Tumor-infiltrating follicular helper T cells: The new kids on the block. OncoImmunology, 2013, 2, e26066.	2.1	34
65	CD4+ follicular helper T cell infiltration predicts breast cancer survival. Journal of Clinical Investigation, 2013, 123, 2873-2892.	3.9	813
66	State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations. Current Gene Therapy, 2009, 9, 459-474.	0.9	109
67	Molecular profiling of CD3â^'CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways. Blood, 2009, 114, 2969-2983.	0.6	34
68	Progressive loss of CD3 expression after HTLV-I infection results from chromatin remodeling affecting all the CD3 genes and persists despite early viral genes silencing. Virology Journal, 2007, 4, 85.	1.4	9
69	Pertussis toxin activates adult and neonatal naive human CD4+ Tâ€„lymphocytes. European Journal of Immunology, 2006, 36, 1794-1804.	1.6	13
70	Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2â€“positive breast cancer cells in a synergistic manner. Molecular Cancer Therapeutics, 2006, 5, 3042-3051.	1.9	58
71	Defective CD3Î³ gene transcription is associated with NFATc2 overexpression in the lymphocytic variant of hypereosinophilic syndrome. Experimental Hematology, 2005, 33, 1147-1159.	0.2	21
72	Transcriptional Regulation of the HumanCD3Î³ Gene: The TATA-LessCD3Î³ Promoter Functions via an Initiator and Contiguous Sp-Binding Elements. Journal of Immunology, 2005, 174, 6238-6249.	0.4	13

#	Article	IF	Citations
73	6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome. Haematologica, 2005, 90, 753-65.	1.7	41
74	Identification of Three NFAT Binding Motifs in the 5â€²-Upstream Region of the Human CD3Î³ Gene That Differentially Bind NFATc1, NFATc2, and NF-ÎºB p50. Journal of Biological Chemistry, 2002, 277, 47136-47148.	1.6	39
75	Human Immunodeficiency Virus Type 2 Produces a Defect in CD3-Î³ Gene Transcripts Similar to That Observed for Human Immunodeficiency Virus Type 1. Journal of Virology, 1999, 73, 5207-5213.	1.5	9
76	Modulation of CD3-Î³ Gene Expression after HIV Type 1 Infection of the WE17/10 T Cell Line Is Progressive and Occurs in Concert with Decreased Production of Viral p24 Antigen. AIDS Research and Human Retroviruses, 1996, 12, 715-725.	0.5	9
77	A comparative analysis of alterations in protein expression after activation or human immunodeficiency virus, type 1 infection of human CD4+ T cells. Electrophoresis, 1991, 12, 544-553.	1.3	4
78	Protein mapping of two metallothionein-rich cell strains and their parent lines, using high-resolution two-dimensional electrophoresis. Analytical Biochemistry, 1984, 143, 170-178.	1.1	11
79	Analysis of Normal Subset-specific and Disease-specific Human Leukocyte Proteins by Cell Sorting and Two-dimensional Electrophoresis. Annals of the New York Academy of Sciences, 1984, 428, 201-222.	1.8	10
80	QUANTITATIVE FLUORESCENCE ANALYSIS OF CYCLOSPORINE BINDING TO HUMAN LEUKOCYTES. Transplantation, 1984, 37, 276-280.	0.5	13